Article Figures & Data
Figures
- FIGURE 1.
Mean biodistribution curves plotted for decay-corrected percentage injected dose per gram of organ mass vs. time. Time axis represents average time over all patients for each PET scan because some patients (i.e., tall patients) required more bed positions. (A) Organs with higher uptake. (B) Organs with lower uptake. (C) Increasing urinary bladder activity. LLI = lower large intestine; SI = small intestine; ULI = upper large intestine. %ID/g = percentage injected dose per gram of organ mass.
- FIGURE 2.
18F-DCFBC PET anterior projection maximal-intensity-projection images at 2 h after injection in patient 1, with several bone metastases (arrow) (A), and patient 5, with LN metastases (arrow) (B), as confirmed by correlation to CT portion of PET/CT exam.
- FIGURE 3.
Examples of concordant findings on 18F-DCFBC PET and CIM: (A) T12 bone metastasis (arrows) seen on bone scan (far right) and (B) retroperitoneal right external iliac LN (arrow) seen on CT (arrow).
- FIGURE 4.
(A and B) Focal 18F-DCFBC PET uptake at aortic bifurcation (arrow, A) with correlative small LN seen on concurrent contrast-enhanced CT (arrow, B), not considered to be nodal metastasis by CT but positive by PET. (C) Retrospective review of prior contrast-enhanced CT scan obtained 1 y previously demonstrates LN in this region (arrow).
- FIGURE 5.
Focal 18F-DCFBC PET uptake in L4 vertebral body on PET and fused PET/CT (thick arrows, A) with no correlative abnormality on CT (thin arrow, A) or bone scan (arrow, B).
- FIGURE 6.
(A) New sclerotic lesion in right posterior iliac bone seen on CT (thin white arrow) but not on 18F-DCFBC PET (black arrow) or PET/CT (thick white arrow). (B) Corresponding asymmetric uptake on bone scan (arrow).
Tables
Organ Average SD Percentage coefficient of variation Adrenals 9.26E−04 2.35E−04 25.43 Brain 1.20E−02 1.30E−03 10.78 Gallbladder contents 2.50E−03 6.87E−04 27.47 Lower large intestine contents 1.40E−02 3.96E−03 28.29 Small intestine contents 4.93E−02 5.35E−03 10.85 Stomach 1.96E−02 3.06E−03 15.55 Upper large intestine contents 1.52E−02 2.55E−03 16.76 Heart contents 4.78E−02 7.26E−03 15.20 Heart wall 2.10E−02 2.58E−03 12.31 Kidneys 3.50E−02 5.84E−03 16.68 Liver 1.59E−01 3.29E−02 20.62 Lungs 1.09E−01 1.87E−02 17.13 Pancreas 5.34E−03 8.93E−04 16.73 Spleen 1.01E−02 8.92E−04 8.80 Testes 2.42E−03 1.00E−03 41.50 Thyroid 8.00E−04 8.23E−05 10.29 Bladder contents 1.26E−01 4.94E−02 39.13 Red marrow (femoral head) 1.08E−01 1.06E−02 9.86 Red marrow (spine) 6.92E−02 7.70E−03 11.12 Total body 2.37E+00 9.09E−02 3.83 Remainder of body 1.72E+00 1.01E−01 5.86 Organ Average SD Percentage coefficient of variation Adrenals 1.85E−02 2.83E−03 15.32 Brain 4.21E−03 2.83E−04 6.73 Breasts 8.51E−03 3.22E−04 3.78 Gallbladder wall 1.79E−02 1.95E−03 10.90 Lower large intestine wall 2.47E−02 3.69E−03 14.92 Small intestine wall 2.36E−02 1.72E−03 7.31 Stomach wall 3.02E−02 3.24E−03 10.72 Upper large intestine wall 2.34E−02 2.20E−03 9.39 Heart wall 2.92E−02 3.24E−03 11.12 Kidneys 2.84E−02 3.81E−03 13.45 Liver 2.46E−02 4.16E−03 16.88 Lungs 2.45E−02 2.99E−03 12.22 Muscle 9.69E−03 3.97E−04 4.10 Ovaries 1.32E−02 5.26E−04 3.99 Pancreas 1.92E−02 2.15E−03 11.19 Red marrow 1.70E−02 9.81E−04 5.79 Osteogenic cells 1.82E−02 8.92E−04 4.90 Skin 7.30E−03 3.50E−04 4.79 Spleen 1.72E−02 1.05E−03 6.08 Testes 1.54E−02 4.19E−03 27.23 Thymus 1.10E−02 4.53E−04 4.12 Thyroid 1.17E−02 6.87E−04 5.88 Bladder wall 3.24E−02 7.24E−03 22.35 Uterus 1.34E−02 2.95E−04 2.20 Total body 1.09E−02 4.28E−04 3.91 Effective dose 1.99E−02 1.34E−03 6.73
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
- Evaluation of an Automated Module Synthesis and a Sterile Cold Kit-Based Preparation of 68Ga-PSMA-11 in Patients with Prostate Cancer
- Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer
- Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer
- Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer
- Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging
- Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer
- Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
- A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer
- PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients
- Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT
- Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging
- Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
- Reply: PSMA Ligands for Imaging Prostate Cancer: Alternative Labeling by Complex Formation with Al18F2+
- PSMA Ligands for PET Imaging of Prostate Cancer
- Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
- Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?
- Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18F-DCFPyL: Variability in Normal-Organ Uptake
- Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging
- Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer
- Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer
- (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted {alpha}-Particle Radiopharmaceutical Therapy
- Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naive and Castration-Resistant Metastatic Prostate Cancer
- New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy
- The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
- 18F-Fluoride PET in the Assessment of Malignant Bone Disease
- Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen
- 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
- 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer
- A Novel 111In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer
- Imaging Active Urokinase Plasminogen Activator in Prostate Cancer
- Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates
- Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
- 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer
- Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer
- AEG-1 Promoter-Mediated Imaging of Prostate Cancer
- PET/MR Imaging: A Critical Appraisal